News Sign up to receive news alerts. Your Email* YOUR EMAIL Havn Life Sciences to support the first modern psilocybin depression study in Germany with MIND Foundation October 30, 2020 Havn Life Sciences earns Health Canada approval for natural health product formulations October 26, 2020 Havn Life Sciences signs agreement to supply psychedelic compounds for use in research and development to Revive Therapeutics October 20, 2020 Havn Life Sciences announces appointment of Dennis Staudt to the Board of Directors & Senior Management Reorganization October 19, 2020 Havn Life applies for licence to produce and sell psilocybin October 13, 2020 Havn Life Sciences announces appointments of Vic Neufeld as Chairman and Rick Brar as Vice Chairman of the Board of Directors, respectively, and the acceleration of Warrants October 5, 2020 Havn Life joins UK Psychedelics Working Group with leading international scientists October 1, 2020 Havn Life Sciences Inc. Reports Q1 Financial Statements September 30, 2020 Havn Life Sciences submits range of natural health products to Health Canada September 23, 2020 Havn Life Sciences announces listing approval on the Frankfurt Stock Exchange September 16, 2020 PRESS RELEASES Havn Life Sciences to support the first modern psilocybin depression study in Germany with MIND Foundation October 30, 2020 Havn Life Sciences earns Health Canada approval for natural health product formulations October 26, 2020 Havn Life Sciences signs agreement to supply psychedelic compounds for use in research and development to Revive Therapeutics October 20, 2020 Havn Life Sciences announces appointment of Dennis Staudt to the Board of Directors & Senior Management Reorganization October 19, 2020 Havn Life applies for licence to produce and sell psilocybin October 13, 2020
